🇺🇸 FDA
Pipeline program

TAK-853

TAK-853-1501

Phase 2 small_molecule active

Quick answer

TAK-853 for Ovarian Cancer is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Ovarian Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials